The thermodynamic behaviour of selected polymeric components for preparation of controlled release microparticles using supercritical carbon dioxide (scCO 2 ) processing was investigated. The polymeric materials selected were egg lecithin (a model for the lung surfactant phospholipid), poly(ethyleneglycol) (PEG) of different molecular weights, fatty acids (C18, C16, and C14), and physical blends of PEGs and fatty acids. In addition a range of PEG-stearates was also assessed. Analysis of thermodynamic behaviour was performed by differential scanning calorimetry (DSC) and by assessment of their interaction with scCO 2 in a high-pressure variable volume view cell. The key criterion was to demonstrate a strong interaction with scCO 2 and to show liquefaction of the polymeric material at acceptable processing temperatures and pressures. Positive results should then indicate the suitability of these materials for processing by the Particle from Gas Saturated Solutions (PGSS) technique using scCO 2 to create microparticles for pulmonary administration. It was found that the materials tested interacted with scCO 2 and showed a sufficient lowering of their melting temperature (T m ) to make them suitable for use in the PGSS microparticle production rig. Fatty acids of low T m were shown to act as a plasticising agent and to lower the T m of PEG further during interaction with scCO 2.
Introduction
In recent years, there has been an increasing interest in delivery of peptides and proteins to the systemic circulation using the pulmonary route. This is due to the relatively high bioavailability achievable after application of such drugs to the lungs, mainly caused by the large surface area of the lungs (140 m 2 ) available for drug absorption, the large blood supply to the pulmonary region and also the presence of a thin alveoli mucous membrane enabling the rapid transport of even large biological drugs across the epithelial membrane (Patton et al., 2004) . Researchers have especially been interested in the development of microparticulate systems for the encapsulation of drugs and delivery mainly to the alveoli for rapid or sustained absorption (Patton, 1996; Cryan, 2005) . Unfortunately, the use of the pulmonary route peptide and protein delivery via the lungs was negatively impacted by the withdrawal of Exubera, the first pulmonary insulin product (in the form of a microparticulate powder formulation), from the market after less than one year, because of low patient and physician acceptance and hence disappointing sales. This resulted in several other pharmaceutical companies terminating their development efforts on pulmonary insulin.
Several defensive and clearance mechanismsz are present in the lungs, to prevent the entry into the body of unwanted particles which may be inert, toxic, carcinogenic, allergenic or infectious (Gehr and Hyder, 2000) . Excessive intake of foreign particles from sources such as polluted air and cigarette smoke, and the subsequent build-up, can cause severe damage and be detrimental to health (Adjei and Gupta, 1997) . Although, drug delivery to the lungs using various delivery systems, such as microparticles, has a long history, the toxicology of the materials used for such systems may not be totally understood. It is therefore important to choose materials well known and accepted for pharmaceutical formulations, such as Generally Recognised AS Safe (GRAS) materials or those already present to some degree in the body, although the biocompatibility of such materials in the lungs may not be known Also, these materials need to be amenable to the formulation technology adopted for production of pulmonary microparticles.
The most common methods used for the encapsulation of drugs such as peptides and proteins using polymer materials, are based on emulsification and/or solvent evaporation techniques, spray drying and extrusion techniques, or combinations or variations thereof. However, most of these methods require either the use of solvents for dissolution of the polymer or high temperatures and hence are not suitable for encapsulation of peptides and proteins, since this would result in loss of bioactivity. The use of a supercritical fluid preparation method such as the Particle from Gas Saturated Solutions (PGSS) technique, for production of microparticles suitable for lung delivery of biological drugs is an attractive alternative to conventional methods, since this method allows processing at low temperature without the involvement of solvents Naylor et al., 2011; Jordan et al., 2010) . The PGSS process relies on the ability of scCO 2 to plasticize or liquefy the materials used for the encapsulation of drugs, by diffusing into the polymer chains, detangling these and thereby lowering the glass transition temperature (T g ) and the melting temperature (T m ). The drug particle generally remains in the solid state and can be mixed with the liquefied polymer material upon which the mixture is solidified (encapsulating the drug) by spraying through a nozzle into a low-pressure environment. The liquefied material must have a low viscosity (when liquefied) to enable spraying into suitably small microparticles in the range of 2-5 m in aerodynamic diameter in order to reach the alveoli after pulmonary administration.
Polymers, such as PLGA and PEG, are commonly used materials for encapsulation of drugs since they are readily available and accepted by regulatory authorities for human use (O'Hara and Hickey, 2000; Coowanitwong et al., 2008; Upton et al., 2010; Naylor et al., 2011) . However, depending on their molecular weight, that governs their crystallinity and permeability to biological fluids, PLGA degrades over at least several weeks or months which would not be suitable for lung administration because of build up of material, whereas PEG is better suited with its general solubility in aqueous solutions (Batycky et al., 1997; Stolnik et al., 1995) .
The phospholipids present in the pulmonary surfactant layer in the alveoli could be a suitable material for use in production of microparticles. The major function of the surfactant is to lower the surface tension at the air-water interface of the alveoli, which reduces the tendency of the alveoli to collapse at the end of expiration (Veldhuizen et al., 1998) . The pulmonary surfactant is composed of approximately 90% lipids and 10% protein. Of the lipids 80% are made up of phosphatidylcholine, with the remaining 20% being cholesterol, triacylglycerol and free fatty acids (Creuwels et al., 1997) . Recently, solid lipid nanoparticles, where the lipid used varies from fatty acids to phospholipids, have gained interest for use in drug delivery (Liu et al., 2008; Mezzena et al., 2009) .
Fatty acids comprise a carboxylic acid group and a hydrocarbon chain of varying length and can be saturated or mono/bisunsaturated. Unsaturated fatty acids are usually liquid at room temperature and are therefore not suitable for a PGSS production process. Saturated fatty acids on the other hand, are usually solid at room temperature and the most common types, stearic and palmitic acids have relatively low melting temperatures of 60-70 • C and hence are better suited for production of particles using the PGSS method.
The interaction of various polymers with scCO 2 is well studied. scCO 2 is able to dissolve in amorphous polymers such as PMMA and PVC (Shieh et al., 1996a) and crystalline polymers such as HDPE (Shieh et al., 1996b) and PEG (Weidner et al., 1997) and thereby reduce the T g and the T m , respectively. Biodegradable polymers such as PLGA and PLA have also been investigated under scCO 2 and a depression in the T g has been observed (Tai et al., 2010; Naylor et al., 2011) . The solubility and the interaction of phospholipids in and with scCO 2 have likewise been studied. However, it is the evaluation of the liquefaction of the lipids in scCO 2 that is important in the PGSS process and this property is not The aim of the present work was to investigate the thermodynamic behaviour of selected pulmonary components such as egg lecithin (used as a model for the lung surfactant phospholipid) and fatty acids during interaction with scCO 2 and to evaluate their suitability for use in production of microparticles using the PGSS technique . Furthermore, the thermodynamic behaviour of free PEG in combination with fatty acids and PEG-derivatised-fatty acids was carried out measuring T m using a high pressure variable volume view cell ("view cell") and DSC.
Materials and methods

Materials
Egg lecithin (90%) was purchased from Fisher Chemical (Leicestershire UK). PEG (MWs 1000, 3000, 3400, 4600 and 6000) were supplied by Fluka (Dorset, UK). Myristic acid, palmitic acid and stearic acid (grade 1, purity >98.5%) were purchased from Sigma Aldrich (Dorset, UK). PEG 100 stearate (PEG MW 4400 Da) ( Fig. 1) , PEG 40 stearate (PEG MW 1760 Da) and PEG 8 stearate (PEG MW 352 Da) were provided by Croda (Yorkshire, UK) and PEG 20 stearate (PEG MW 880 Da) by Adina (Kent, UK). CO 2 pharmaceutical grade was supplied by BOC. All reagents were used as received.
High pressure variable volume view cell ("view cell")
The temperatures and CO 2 pressures required to observe phase changes in egg lecithin, PEG, fatty acids and the blends were determined using a view cell. The view cell containing optically transparent sapphire windows was developed by License et al. (2004) . The system consists of three main units; a view cell, a moderated hydraulic pressure intensifier/positional ram, and an integrated, electronic remote control unit (Fig. 2) . The view cell body and head units are made from stainless steel (316 SS) which house a sapphire window and a transparent moveable sapphire piston. The view cell allows the observation of the phase behaviour of materials under scCO 2 . In the present work, the temperature and pressure at which materials become liquid in scCO 2 is of particular interest, as it can be applied to the PGSS process. In a typical experiment, the materials (∼2 g) were weighed into the view cell along with a magnetic stirrer and the front sapphire window assembled. CO 2 was added to the view cell through the inlet valve. The view cell was heated to 35 • C and the pressure was slowly increased to approximately 140 bar, whilst observing the sample for any changes. Once at the required temperature, the pressure was slowly increased to 340 bar. After being held at this pressure for 10 min, it was reduced to 140 bar. This process was carried out at 35, 45, 55, 65 and 75 • C, allowing the sample to equilibrate at each temperature for 1 h. A magnetic stirrer was used within the view cell to qualitatively assess the viscosity of the materials.
Differential scanning calorimetry (DSC)
The thermal behaviour of the selected samples was analysed using a TA-Q2000 differential scanning calorimeter (TA instruments), calibrated with an indium standard. Typically, the sample (2-5 mg) was weighed into a Tzero DSC pan. This pan was sealed with a Tzero DSC lid using a Tzero press containing a Black Tzero lower die and a flat die. A temperature range of 0-100 • C was scanned using a heating rate of 10 • C/min. The melting temperature of the material was recorded as T m and each measurement was performed in triplicate.
Statistical methods
Statistical analyses were performed where possible, using Microsoft Excel. Analyses were calculated using one-way ANOVA and any differences in the results were considered significant if the p-value was less than 0.05.
Results and discussion
Egg lecithin
Egg lecithin was used as a model for the phospholipids that are found in lung surfactant, and is a mixture of different phospholipids such as diacylphosphatidylethanolamines and phosphatidylcholine and is 90% pure. The exact composition of the phospholipids and the nature of the impurities were not known. When the egg lecithin was exposed to scCO 2 at temperatures up to 75 • C and pressures of 345 bar in the high-pressure view cell no changes or softening of the egg lecithin was observed (Fig. 3) . The melting temperature of phospholipid is quite high e.g. diacylphosphatidylethanolamines and phosphatidylcholine have melting temperatures of about 200 • C and 230 • C, respectively. It was not necessary to evaluate processing temperatures above 75 • C since this would be unsuitable for peptide and protein encapsulation. Clearly egg lecithin (phospholipids) is not suitable for processing in a PGSS microparticle production process.
The low solubility of pure phospholipids in scCO 2 has been observed by other research groups when trying to extract lipidic products from a natural source (Montanari et al., 1999; Teberikler et al., 2001; King, 2004) . To improve this process, polar co-solvents have been used to enhance the solubility for extraction and purification by supercritical fluid techniques (Teberikler et al., 2001) . Therefore, ethanol and methanol were introduced into the view cell along with scCO 2 to assess the effect upon egg lecithin. As little as 0.5 ml ethanol clearly introduced semi-liquefaction of the 0.5 g egg lecithin (Fig. 4) . Increasing the amount of ethanol to 1 ml or replacing it with 0.5 ml of methanol led to complete liquefaction. The introduction of the polar solvents changes the polarity of the scCO 2 , which meant that an interaction was possible with egg lecithin. Hence, from these experiments it can be concluded, that egg lecithin is only suitable for preparation of particles using the PGSS method if polar solvents such as ethanol or methanol are introduced into the process.
Fatty acids
Possible substitutes for phospholipids are fatty acids, which form an important constituent of the phospholipid structure and are also present in lung surfactant. Fatty acids have previously been used to prepare solid lipid nanoparticles (Liu et al., 2008) . In the present work stearic, palmitic and myristic acids were selected for investigation, because the former two are commonly found in nature and since myristic acid has a lower melting temperature. The fatty acid characteristics and melting temperature as measured by DSC and evaluated in the view cell are shown in Table 1 and Fig. 5 . The DSC thermographs show single T m peaks. The view cell experiments demonstrated that at 140 bar, a 10-15 • C depression in T m for the fatty acids, was observed when exposed to scCO 2 . The depression in T m was largest (15 • C) for the myristic acid with the shortest fatty acid chain length, which was most likely due to a higher solubility of the scCO 2 in the less rigid (less crystalline) structure of myristic acid as compared to stearic acid (10 • C).
When liquefied, all three fatty acids formed clear liquids. The behaviour of fatty acids has been investigated by several research groups but only in relation to fractionation and extraction from mixtures of natural products (Guclu- Ustundag and Temelli, 2005; Bamberger et al., 1988; Garlapati and Madras, 2010) . Of the fatty acids investigated, myristic acids melted at 40 • C and 15 MPa (150 bar) in agreement with the results presented here. These authors also noted, that palmitic acid did not melt, whereas our data demonstrate that a slightly higher temperature is required. It can be concluded that all three of the fatty acids tested here showed thermodynamic properties that would be suitable for use in the PGSS particle production.
Polyethyleneglycol (PEG)
PEG is a material with suitable characteristics for pharmaceutical use and for microparticle production using the PGSS method in particular (Naylor et al., 2011) . It is a GRAS material and hence nontoxic with approval by regulatory authorities for oral and parenteral pharmaceutical use. At molecular weights below 1000 Da, PEG exists as a colourless viscous liquid, and above as a white waxy solid. The T m is normally proportional to the molecular weight, reaching a plateau of 67 • C. Furthermore, PEG is water soluble enabling it to be dissolved in body fluids and quickly cleared (Harris, 1992) . A range of PEGs with different molecular weights from 1000 Da to 6000 Da were investigated using DSC (Fig. 6 ) and in the view cell under scCO 2 . The PEGs were not melted and recrystallised before use to better mimic the PGSS microparticle production process. The PEGs melting temperatures as measured by DSC are shown in Fig. 6 and Table 2 and the T m values as evaluated in the view cell under scCO 2 are shown in Table 2 .
The different PEGs evaluated in the study all showed single T m peaks and as expected the T m values were found to decrease with decreasing molecular weight, with a T m for PEG 6000 of 62.7 • C and of 37.5 • C for PEG 1000 (Fig. 6 and Table 2). As observed for the fatty acids, a depression in T m of all PEG polymers was observed in the presence of scCO 2 . Due to the low starting T m of PEG 1000 the polymer was liquefied already at room temperature, before CO 2 reached the critical point. For all other PEG molecular weights, the material remained solid until exposed to scCO 2 . As can be seen from Table 2 , all T m s were significantly reduced.
The reduction in T m can be attributed to the dissolution of scCO 2 in PEG. Applying a pressure to a substance often results in an increase in melting temperature (Greenwald et al., 2003) . However, the effect of hydrostatic pressure is more than overcome by the absorption of scCO 2 into the polymer that swells the matrix and increases the free volume between the chains. Therefore, scCO 2 acts as molecular lubricant, increasing the segmental and chain mobility and increasing the inter-chain distance (King, 2004) . The gaseous properties of scCO 2 mean that it is ideal to diffuse between the polymer chains. This process is more efficient in amorphous regions of the polymer than in crystalline regions, since here less hindrance is found, because of a lack of regular structure and high density of interactions (Shieh et al., 1996a,b) . Consequently, there is a competition between the effect of the high pressure and scCO 2 . Weidner et al. (1997) showed that up to approximately 10 bar (145 psi) the liquefaction temperature increased. At a pressure above 10 bar the T m in scCO 2 decreases. However, as the pressure increases further, the effect of scCO 2 in reducing the T m then becomes outweighed by the hydrostatic pressure, and the temperature of the solid-liquid transition begins to increase. For PEG with molecular weights of 1500, 4000 and 35,000 this upper limit is between 210 bar and 240 bar (Greenwald et al., 2003) . Therefore, when PEG is used in the PGSS process it is more efficient to work below this pressure.
PEG-stearates
PEG-stearates are molecules comprised of PEG chemically bonded to stearic acid through an ester linkage, and combine the functionalities of both PEG and stearate in the same molecule.
These chemicals are generally used in the cosmetic industry in products such as moisturisers and as emulsifying agents and surfactants (Teberikler et al., 2001 ). The different PEG-stearates used in the experiments are listed in Table 3 . The number in the nomenclature refers to the number of ethylene glycol units present in the molecule. It is first of all evident that all of the PEG-stearates have melting temperatures that are lower than both the individual T m of stearic acid (71.8 • C) and of a similar molecular weight PEG (Tables 1 and 2 ). The behaviour of these materials was investigated in scCO 2 and compared to their T m under atmospheric conditions (Table 3) .
There are very few examples of PEG-stearates used in drug delivery and no instances of these materials being evaluated in scCO 2 (Teberikler et al., 2001; Clifford, 1999) . In scCO 2 , PEG-stearates exhibit a depression in T m and give a clear substance which is easily stirred, similar to fatty acids and PEG. It is clear that the PEG stearates can be processed using scCO 2 and it is likely that they would be suitable for the preparation of microparticles using the PGSS process.
Fatty acid and PEG blends
As discussed above, the PEG-stearates exhibited a lower T m than the individual PEG and stearic acid components, and hence it was investigated whether a physical mixture of PEG and stearic acid in a similar way would have a lower T m . It is known that two physically mixed polymers often behave similarly to their chemically bonded copolymers (Bamberger et al., 1988) . Therefore, a PEG:fatty acid (1:1, w/w) ratio was used to investigate the effect of a physical blending on the T m as measured by DSC and in the view cell under scCO 2 .
The DSC traces for a 1:1 blend of PEG 6000 with the three different fatty acids are shown in Fig. 7 . In comparison, the DSC traces for the individual components of PEG 6000 (T m −62.7 • C), stearic acid (18 carbon atoms, T m −71.8 • C), palmitic acid (16 carbon atoms, T m −62.6 • C), and myristic acid (14 carbon atoms, T m −54.3 • C) are For both of the blends containing myristic and palmitic acids a single peak is present between the T m of the two separate materials indicating formation of a blend. Myristic acid interacted with PEG 6000 and reduced the T m of the blend to a value that is close to that of myristic acid whereas the PEG 6000:palmitic acid blend remained around 63 • C, similar to the two components. The trace for the PEG:stearic acid blend shows the presence of two peaks, not entirely separated. This is due to the low T m of PEG 6000 (62.7 • C) combined with the high T m of stearic acid (71.8 • C). This broadening of the T m range and shift towards lower values have been reported previously and can be explained by PEG/fatty acid acting as an impurity for each other and disrupting the crystalline structure (Pielichowski and Flejtuch, 2003) . The blends prepared with PEG 4600, PEG 3400 and PEG 3000 and the three different fatty acids showed similar results to those prepared with PEG 6000 (Table 4) , whereas the blends prepared with PEG 1000 showed different thermal behaviour. By contrast, the DSC traces for 1:1 blends of PEG 1000 clearly show two peaks. The T m values of the blends are slightly lower than those of PEG 1000 and the individual fatty acids. This suggests that some interaction, such as hydrogen bonding between the fatty acid and PEG molecules, has occurred which resulted in the disruption of the crystalline structure and subsequent reduction in T m .
When the blends were exposed to scCO 2 , the material with the lowest T m value was seen to liquefy first leaving the other material solid (data not shown). As the temperature was increased above the T m of the second material, a single clear liquid was formed. There was no observed reduction in the T m of the fatty acids in the presence of PEG. However, when a fatty acid with a temperature lower than the PEG was used, the T m of PEG was reduced. One possible explanation for this is that the liquefied fatty acid molecules infiltrate and disrupt the crystalline PEG lattice. As stearic acid liquefies after PEG, it cannot penetrate the lattice and therefore has no effect on the melting of PEG in scCO 2 .
Conclusion
The thermodynamic behaviour in terms of T m of selected pulmonary components such as egg lecithin and fatty acids were evaluated both by DSC and in a view cell during interaction with scCO 2 . On the basis of this data, their suitability for use in production of microparticles using the PGSS technique based on supercritical carbon dioxide scCO 2 , was assessed . The key criterion is to show that the polymer material (phospholipid or fatty acid) has sufficient interaction with scCO 2 to be liquefied under accessible pressures and temperatures and to enable the mixing with solid drug particles to produce microparticles encapsulating the drug, after venting the scCO 2 -polymer-drug mixture into a lower pressure chamber. It is important for the production of microparticles using the PGSS production technique that the viscosity of the liquefied polymer(s) is low. The viscosity has in general been shown by our group to be directly related to the T m of the polymer or polymer mixture used.
The generally high melting temperatures of phospholipids resulted in the egg lecithin showing no interaction with scCO 2 and remaining solid at a temperature of 75 • C and high (345 bar) pressure of scCO 2 in the view cell, and hence egg lecithin was not investigated further. As fatty acids are an important constituent of phospholipids, three fatty acids, stearic acid, palmitic acid and myristic acid with the lowest T m were investigated. A 10-15 • C depression in the T m was observed when the fatty acids were exposed to scCO 2 . PEG and PEG-stearates were also exposed to scCO 2 with similar results. Furthermore, blends of different molecular weight PEGs and different fatty acids were also exposed to scCO 2 in order to evaluate the effect of a physical blending compared to chemical bonding of the components. The chemically bonded PEG-stearates generally showed a single T m peak, whereas the Tm peaks for the physical blends for all PEG molecular weights and fatty acids in general showed a double peak with two distinguishable T m values. It was observed in the physical blends, that if the fatty acid had a lower melting point than the PEG, it could act as a plasticising agent and reduce the T m in scCO 2 . However PEG did not have that effect on fatty acids. The materials evaluated here are solid at room temperature and can be liquefied at relatively low temperatures using scCO 2 . They are also generally used in pharmaceuticals and cosmetics suggesting that they might be suitable for preparing particles for pulmonary drug delivery using the PGSS process.
